Cp-pca07

Phase 1

Cp-pca07 is one of 3 therapeutic programs targeting Castration-Resistant Prostate Cancer (CRPC). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Castration-Resistant Prostate Cancer (CRPC)Not yet recruiting

Castration-Resistant Prostate Cancer (CRPC)Phase 1

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Castration-Resistant Prostate Cancer (CRPC)

#DrugCompanyPhaseTrials

Erleada

Johnson & Johnson

Phase 2

1 2

Oral MRT-2359

MMonte Rosa Therapeutics, Inc

Phase 2

1 3

Cp-pca07

HHyundai Bioscience Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Castration-Resistant Prostate Cancer (CRPC)

NCT07683013

Clinical

Trials by Indication[1]

Castration-Resistant Prostate Cancer (CRPC)1 trial

An Open-Label, Dose-Escalation, Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer

Not yet recruiting·HHyundai Bioscience Co., Ltd.·Phase 1·NCT07683013·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cp-pca07. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Cp-pca07. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Hyundai Bioscience Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: HHyundai Bioscience Co., Ltd.

Cp-pca07

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Castration-Resistant Prostate Cancer (CRPC)1 trial

References

Drug Info

Quick Facts

Related News